Considering its modest efficacy in mitigating angina symptoms and the rate of side effects amongst participants, this underscores the necessity for further investigations to substantiate and validate the therapeutic potential of modulating the ET-1 pathway in the management of CSFP. This evidence concerns the gene EDN1 and angina pectoris.